MedTrace Logo

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

NCT01080248 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2015-06-09

Study results available
· View outcomes & findings →

Summary

To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Gemcitabine

DRUG

Pazopanib

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Joel Picus, M.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2010-12-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01080248 on ClinicalTrials.gov